Pharmacokinetic (PK) Study of OxyNorm Injections in Chinese Patient

Inclusion Criteria: * Patients with tumor pain / postoperative pain, or subjects with pain caused by other diseases; * Patients aged \>30 to ≤ 60 years; * Body weight ≥ 45kg, and BMI range ≥19, \<24; * Karnofsky score ≥ 70; * Expected survival is above 3 months; * The results of liver function and kidney tests must meet the following criteria:ALT、AST is within the upper limit of normal value ranges by a factor 2, and TB、BUN、Cr is within the upper limit of normal value ranges by a factor 1.25; * The electrocardiogram examination results are normal; * Patients must have given a written informed consent prior to this trial, and have the capability to complete every required test. Exclusion Criteria: * Have hypersensitivity history to any opioids; * Have known hypersensitivity to any of compositions of the study drugs; * Patients who are likely to have paralytic ileus or acute abdomen or to perform an operation on abdominal region； * Patients with respiratory depression, cor pulmonary, or chronic bronchial asthma; * Patient unable to stop taking monoamine oxidase inhibitor during this trial period or time lapses less than 2 weeks since drug withdrawal; * Patients with hypercarbia; * Patients with biliary tract diseases, pancreatitis, prostatic hypertrophy, or corticoadrenal insufficiency; * Patients with alcoholism or drug abuse history; * Positive ant-HIV or syphilis antibody test result; * Urine screening before study is positive for the opioids, barbiturates, amphetamines, cocaine metabolites, methadone, diazepam and cannabinoids; * Donated 400 mL or more of blood or blood products within 3 months prior to the start of the study, or donated 200 mL or more of blood or blood products within one month prior to the start of the study. * Subjects who participated in a clinical research study within two months of study entry. * Patients who are currently taking opioids.